New York is currently home to 4504 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Randomized Multicenter Study for Isolated Skin Vasculitis
Recruiting
Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Northwell Health, Lake Success, New York
Conditions: Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance
Recruiting
This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active surveillance (AS). AS in prostate cancer involves closely watching the patient's condition through regular physical exams and blood tests, but not giving treatment unless there are changes in test results. It can be a practical alternative to treatment in localized prostate... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia
Recruiting
Subjects who have enrolled in the oculopharyngeal muscular dystrophy (OPMD) natural history study (Study BNTC-OPMD-NH-001) and have completed at least 6 months of follow up in Study BNTC-OPMD-NH-001 may be eligible to participate in this study, where all subjects will be treated with a single dose of BB-301. BB-301 will be injected directly into the middle pharyngeal constrictor muscle and the inferior pharyngeal constrictor muscle of the throat through the use of an open surgical procedure cond... Read More
Gender:
ALL
Ages:
65 years and below
Trial Updated:
02/03/2025
Locations: NYU Langone Health, New York, New York
Conditions: Oculopharyngeal Muscular Dystrophy
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Recruiting
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Weill Cornell Medicine NewYork-Presbyterian, New York, New York
Conditions: Myelofibrosis, Moderate Thrombocytopenia
SELUTION 4 De Novo Small Vessel IDE Trial
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Coronary Artery Disease
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Recruiting
The study is being done to see if the combination of ruxolitinib and abemaciclib is a safe and effective treatment for people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Memorial Sloan Kettering Suffolk - Commack, Commack, New York
Conditions: Myelofibrosis Due to and Following Polycythemia Vera
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Recruiting
The study will evaluate how safe the study drug is, how well you tolerate it, and how it works in the body and the disease's response to the drug. The study drug being tested is sarilumab, when given with the combination of ipilimumab, nivolumab, and relatlimab in patients with stage III or stage IV melanoma that cannot be removed by surgery. Previous studies have provided a strong rationale for combining sarilumab, with ipilimumab, nivolumab and relatlimab in metastatic melanoma to reduce side... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/03/2025
Locations: NYU Langone Health, New York, New York
Conditions: Melanoma, Unresectable Melanoma
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Mount Sinai Health System, New York, New York
Conditions: Myelofibrosis
Study Assessing CLENPIQ As Bowel Preparation for Pediatric Colonoscopy
Recruiting
Bowel preparation for pediatric colonoscopy.
Gender:
ALL
Ages:
Between 2 years and 8 years
Trial Updated:
02/03/2025
Locations: Ferring Investigational Site, Bronx, New York
Conditions: Bowel Preparation
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
Recruiting
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral o... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/03/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Mild Cognitive Impairment, Aging
Pilot Trial of Homebound Stem Cell Transplantation
Recruiting
In this study, the investigators plan to see what happens when a person receives care in the home setting. They want to find out if caring for a patient who has been treated with an ASCT in the home setting is feasible. They want to find out what effects good and/or bad this will have on the patient's recovery and treatment after ASCT. Studies in other institutions have shown that providing care in the home setting after ASCT is safe, increases patient satisfaction, and can decrease the risk of... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/03/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Plasma Cell Dyscrasia